These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640 [TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. André T; Cohen R; Salem ME Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834 [TBL] [Abstract][Full Text] [Related]
7. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582 [TBL] [Abstract][Full Text] [Related]
8. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
9. Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment. Hong JH; Woo IS Cancer Lett; 2023 Jul; 565():216236. PubMed ID: 37209943 [TBL] [Abstract][Full Text] [Related]
10. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142 [TBL] [Abstract][Full Text] [Related]
11. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945 [TBL] [Abstract][Full Text] [Related]
12. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787 [TBL] [Abstract][Full Text] [Related]
13. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406 [TBL] [Abstract][Full Text] [Related]
14. Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors. Salewski I; Kuntoff S; Kuemmel A; Feldtmann R; Felix SB; Henze L; Junghanss C; Maletzki C Cancer Immunol Immunother; 2021 Dec; 70(12):3405-3419. PubMed ID: 33870463 [TBL] [Abstract][Full Text] [Related]